Henk R. van Buuren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henk R. van Buuren has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Rosalie C. Oey
Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
3 shared publications - Nicole Stephanie Erler
Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands
2 shared publications Robert A. de Man
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
2 shared publicationsA. M. C. Baven-Pronk
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
1 shared publicationA. P. van Den Berg
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publication- Adriaan Moelker
Department of Radiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Recurrent Symptomatic Biliary Obstruction due to Duodenobiliary Reflux of Food: A Largely Unknown Complication of Endoscopic Biliary Sphincterotomy
Background and Study Aims Biliary obstruction caused by food is a little known and rarely reported long-term complication of endoscopic sphincterotomy (ES). This retrospective study aimed to characterize patients diagnosed with this condition between 2012 and 2025 and to assess the outcomes of surgical therapy. Patients and Methods Patients were selected who were diagnosed with symptomatic duodenobiliary reflux of food (DBR-F) after earlier ES and who all underwent hepaticojejunostomy with partial resection or ligation of the common bile duct (CBD). DBR-F was diagnosed by pathologic examination of material extracted from the CBD during episodes of biliary obstruction. Data were assessed retrospectively using the hospital electronic patient record system. Long-term outcomes and satisfaction with treatment were also evaluated using a questionnaire. Results We identified 12 patients who had undergone multiple ERCPs for “stone” or “sludge” removal (presurgery median 9, IQR 7.3–10) with microscopic proof of DBR-F. Patients presented with (episodic) abdominal pain, often associated with cholangitis. Liver abscesses were diagnosed in two cases. The median diagnostic delay was 3.3 years. Medical (antibiotics, ursodeoxycholic acid) and endoscopic (repeat sphincterotomy, stenting) treatment were ineffective. Surgical complications were observed in 4/12 (33%) patients. Long-term patient satisfaction after surgery was excellent in 9/10 evaluable patients. Conclusions This single-center series suggests that DBR-F is a long-term complication of ES that must be more prevalent than is suggested by anecdotal literature. This diagnosis should be considered when patients present with recurrent “stones” or “sludge” after previous ES. In selected patients with recurrent significant symptoms associated with DBR-F, surgical therapy is an effective option.
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Open AccessRecurrent Symptomatic Biliary Obstruction due to Duodenobiliary Reflux of Food: A Largely Unknown Complication of Endoscopic Biliary Sphincterotomy
Background and Study Aims Biliary obstruction caused by food is a little known and rarely reported long-term complication of endoscopic sphincterotomy (ES). This retrospective study aimed to characterize patients diagnosed with this condition between 2012 and 2025 and to assess the outcomes of surgical therapy. Patients and Methods Patients were selected who were diagnosed with symptomatic duodenobiliary reflux of food (DBR-F) after earlier ES and who all underwent hepaticojejunostomy with partial resection or ligation of the common bile duct (CBD). DBR-F was diagnosed by pathologic examination of material extracted from the CBD during episodes of biliary obstruction. Data were assessed retrospectively using the hospital electronic patient record system. Long-term outcomes and satisfaction with treatment were also evaluated using a questionnaire. Results We identified 12 patients who had undergone multiple ERCPs for “stone” or “sludge” removal (presurgery median 9, IQR 7.3–10) with microscopic proof of DBR-F. Patients presented with (episodic) abdominal pain, often associated with cholangitis. Liver abscesses were diagnosed in two cases. The median diagnostic delay was 3.3 years. Medical (antibiotics, ursodeoxycholic acid) and endoscopic (repeat sphincterotomy, stenting) treatment were ineffective. Surgical complications were observed in 4/12 (33%) patients. Long-term patient satisfaction after surgery was excellent in 9/10 evaluable patients. Conclusions This single-center series suggests that DBR-F is a long-term complication of ES that must be more prevalent than is suggested by anecdotal literature. This diagnosis should be considered when patients present with recurrent “stones” or “sludge” after previous ES. In selected patients with recurrent significant symptoms associated with DBR-F, surgical therapy is an effective option.
- Open Access
- 22 August 2018
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 48 (9) , 975-983
Variable efficacy of TIPSS in the management of ectopic variceal bleeding: a multicentre retrospective study
Summary: Background: Evidence for the efficacy of TIPSS in ectopic variceal bleeding (EctVB) is largely based on relatively small series.Aim: To define the efficacy of TIPSS in EctVB.Methods: Retrospective analysis of consecutive patients with chronic liver disease who presented with EctVB and received TIPSS in three tertiary centres in 1992‐2016.Results: The study included 53 patients (70% male, median age 61 years, median model for end‐stage liver disease (MELD) score 11). The ectopic varices were located around the insertion of stomas (40%), duodenum (23%), rectum (17%) and at other sites (20%). Three‐quarters of the patients had previously received unsuccessful medical, endoscopic or surgical therapy. The median follow‐up was 14.0 months. Following TIPSS, bleeding recurred in 12 patients: 6 of 12 (50%) with duodenal varices, 2 of 9 (22%) with rectal varices and one each with stomal (1/21), intraperitoneal (1/3), hepaticojejunostomy (1/2) and ascending colon varices (1/2). The risk factors for re‐bleeding were MELD score at TIPSS placement (HR: 1.081 per point; 95% confidence interval (CI): 1.012‐1.153; P = 0.034), varices located at site other than an enterostomy (HR: 9.770; 95%CI: 1.241‐76.917; P = 0.030) and previous local therapy (HR: 5.710; 95%CI: 1.211‐26.922; P = 0.028). The estimated cumulative re‐bleeding rate was 23% at 1 year, 26% at 3 years and 32% at 5 years. Post‐TIPSS hepatic encephalopathy manifested or worsened in 16 of 53 patients (30%).Conclusion: TIPSS provides long‐term control of bleeding in most cirrhotic patients with EctVB. TIPSS is particularly effective in stomal EctVB, the most frequent cause of EctVB, but might not be as effective in duodenal EctVB.
- 22 August 2018
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 48 (9) , 975-983
Open AccessVariable efficacy of TIPSS in the management of ectopic variceal bleeding: a multicentre retrospective study
Summary: Background: Evidence for the efficacy of TIPSS in ectopic variceal bleeding (EctVB) is largely based on relatively small series.Aim: To define the efficacy of TIPSS in EctVB.Methods: Retrospective analysis of consecutive patients with chronic liver disease who presented with EctVB and received TIPSS in three tertiary centres in 1992‐2016.Results: The study included 53 patients (70% male, median age 61 years, median model for end‐stage liver disease (MELD) score 11). The ectopic varices were located around the insertion of stomas (40%), duodenum (23%), rectum (17%) and at other sites (20%). Three‐quarters of the patients had previously received unsuccessful medical, endoscopic or surgical therapy. The median follow‐up was 14.0 months. Following TIPSS, bleeding recurred in 12 patients: 6 of 12 (50%) with duodenal varices, 2 of 9 (22%) with rectal varices and one each with stomal (1/21), intraperitoneal (1/3), hepaticojejunostomy (1/2) and ascending colon varices (1/2). The risk factors for re‐bleeding were MELD score at TIPSS placement (HR: 1.081 per point; 95% confidence interval (CI): 1.012‐1.153; P = 0.034), varices located at site other than an enterostomy (HR: 9.770; 95%CI: 1.241‐76.917; P = 0.030) and previous local therapy (HR: 5.710; 95%CI: 1.211‐26.922; P = 0.028). The estimated cumulative re‐bleeding rate was 23% at 1 year, 26% at 3 years and 32% at 5 years. Post‐TIPSS hepatic encephalopathy manifested or worsened in 16 of 53 patients (30%).Conclusion: TIPSS provides long‐term control of bleeding in most cirrhotic patients with EctVB. TIPSS is particularly effective in stomal EctVB, the most frequent cause of EctVB, but might not be as effective in duodenal EctVB.
- Open Access
- 11 July 2018
- Published by Wiley in Liver International
- Vol. 38 (12) , 2199-2209
Bacterascites: A study of clinical features, microbiological findings, and clinical significance
Background: Knowledge about bacterascites is limited and management guidelines are based on small patient series. The purpose of this study was to add further insight into the clinical characteristics, microbiological findings, and prognosis of patients diagnosed with bacterascites.Methods: Retrospective analysis of patients with advanced chronic liver disease diagnosed with bacterascites andSBPbetween January 2003 and August 2016.Results: In this study, 123 patients were included with 142 episodes of bacterascites. The medianMELDscore was 20 and clinical symptoms of infection were present in 78%. Empiric antibiotic treatment was initiated in 68%. In 26 untreated patients undergoing repeated paracentesis, 42% were diagnosed with either ongoing bacterascites orSBP. The presence of signs or symptoms of infection was not an independent predictor for mortality or spontaneous resolution of infection. The 1‐month and 1‐year mortality rates of the 123 patients studied, were 32% and 60%, respectively; these results were in line with data pertaining to the prognosis ofSBP.Conclusions: Patients with bacterascites andSBPare highly comparable with respect to severity of liver disease and overall prognosis. If left untreated, bacterascites is likely to persist or to evolve toSBPin a significant proportion of patients. The results of this study support current guidelines regarding the treatment of ascitic fluid infection, but could not confirm the prognostic relevance of symptomatic disease at the time of diagnosis. We suggest that the threshold to initiate antibiotic treatment, in particular in cases with severely advanced liver disease, should be low.
- 11 July 2018
- Published by Wiley in Liver International
- Vol. 38 (12) , 2199-2209
Open AccessBacterascites: A study of clinical features, microbiological findings, and clinical significance
Background: Knowledge about bacterascites is limited and management guidelines are based on small patient series. The purpose of this study was to add further insight into the clinical characteristics, microbiological findings, and prognosis of patients diagnosed with bacterascites.Methods: Retrospective analysis of patients with advanced chronic liver disease diagnosed with bacterascites andSBPbetween January 2003 and August 2016.Results: In this study, 123 patients were included with 142 episodes of bacterascites. The medianMELDscore was 20 and clinical symptoms of infection were present in 78%. Empiric antibiotic treatment was initiated in 68%. In 26 untreated patients undergoing repeated paracentesis, 42% were diagnosed with either ongoing bacterascites orSBP. The presence of signs or symptoms of infection was not an independent predictor for mortality or spontaneous resolution of infection. The 1‐month and 1‐year mortality rates of the 123 patients studied, were 32% and 60%, respectively; these results were in line with data pertaining to the prognosis ofSBP.Conclusions: Patients with bacterascites andSBPare highly comparable with respect to severity of liver disease and overall prognosis. If left untreated, bacterascites is likely to persist or to evolve toSBPin a significant proportion of patients. The results of this study support current guidelines regarding the treatment of ascitic fluid infection, but could not confirm the prognostic relevance of symptomatic disease at the time of diagnosis. We suggest that the threshold to initiate antibiotic treatment, in particular in cases with severely advanced liver disease, should be low.
- 21 July 2017
- Published by Frontiers Media SA in Transplant International
- Vol. 30 (8) , 807-816
The impact of infections on delisting patients from the liver transplantation waiting list
Approximately 20% of the patients listed for liver transplantation die before transplantation can be accomplished. Understanding risk factors for waiting list mortality may help to improve survival and organ allocation. Infections are very common in patients with cirrhosis and are associated with significant morbidity and mortality. This study analysed the frequency and characteristics of infections in patients awaiting liver transplantation, identified risk factors for withdrawal from the waiting list and evaluated the impact of infections on the clinical outcome. A retrospective analysis of consecutive patients listed for liver transplantation in Rotterdam, the Netherlands from 2007 to 2014 was conducted. Infections occurred in 144 of 327 studied patients (44%). In this cohort, 23.4% of the patients on the liver transplantation waiting list were delisted or died before transplantation. Patients with an infection were 5.2 times more likely to become delisted than noninfected patients. In the 30 days after the first infection, patients were 33.8 times more likely to become delisted compared to noninfected patients. High age, high MELD score, refractory ascites and inappropriate antibiotic therapy were independent predictors for delisting due to infection. Infections occur frequently in patients on the liver transplantation waiting list. Emphasis on appropriate and timely antimicrobial therapy is required.
- 21 July 2017
- Published by Frontiers Media SA in Transplant International
- Vol. 30 (8) , 807-816
The impact of infections on delisting patients from the liver transplantation waiting list
Approximately 20% of the patients listed for liver transplantation die before transplantation can be accomplished. Understanding risk factors for waiting list mortality may help to improve survival and organ allocation. Infections are very common in patients with cirrhosis and are associated with significant morbidity and mortality. This study analysed the frequency and characteristics of infections in patients awaiting liver transplantation, identified risk factors for withdrawal from the waiting list and evaluated the impact of infections on the clinical outcome. A retrospective analysis of consecutive patients listed for liver transplantation in Rotterdam, the Netherlands from 2007 to 2014 was conducted. Infections occurred in 144 of 327 studied patients (44%). In this cohort, 23.4% of the patients on the liver transplantation waiting list were delisted or died before transplantation. Patients with an infection were 5.2 times more likely to become delisted than noninfected patients. In the 30 days after the first infection, patients were 33.8 times more likely to become delisted compared to noninfected patients. High age, high MELD score, refractory ascites and inappropriate antibiotic therapy were independent predictors for delisting due to infection. Infections occur frequently in patients on the liver transplantation waiting list. Emphasis on appropriate and timely antimicrobial therapy is required.
- Open Access
- 19 August 2011
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 34 (6) , 684-685
Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes: authors’ reply
- 19 August 2011
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 34 (6) , 684-685
Open AccessMycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes: authors’ reply